Friedreich Ataxia研究结果显示，Lexeo股价下跌24%

2024-07-16 00:03

Shares of Lexeo Therapeutics (NASDAQ:LXEO) tumbled 24% after the company reported interim Phase 1/2 clinical data for its drug LX2006 for the treatment of Friedreich Ataxia, or FA, cardiomyopathy.
Lexeo said that based on the drug’s observed safety profile and clinical benefits, it plans to explore expedited development for the product, including possible accelerated regulatory approval. The company noted that there are currently no approved treatments for FA cardiomyopathy, according to a statement.
The company plans to share additional details of the results at a scientific conference in the fall.
Last year, Biogen’s (BIIB) Skyclarys became the first FDA-approved prescription drug to treat FA, a progressive neuromuscular disease that can also cause cardiomyopathy and diabetes.
Other companies working on treatments for FA include Larimar Therapeutics (LRMR), PTC Therapeutics (PTCT), Astellas (OTCPK:ALPMF) (OTCPK:ALPMY), Voyager Therapeutics (VYGR), Design Therapeutics (DSGN), Prime Medicine (PRME) and Solid Biosciences (SLDB).

More on Lexeo Therapeutics